MedTrace Logo

A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.

NCT07575906 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-05-13

No results posted yet for this study

Summary

The purpose of this clinical trial is to learn about the safety and pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from body after participants take it) of the study medicine (called PF-08057418) in healthy people.

This study is seeking participants who are healthy adults.

Everyone who participates in this study will receive the study medicine. The study medicine may be given as a solution or as a tablet. Participants will be dosed once a week for 5 weeks.

The investigators will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe.

Participants will be involved in this study for up to 13 weeks from screening to follow-up visit. Participants stay in the study clinic for the 5 week dosing duration of the study, with two follow-up visits subsequently, either in person or by telephone call.

Conditions

  • Healthy

Interventions

DRUG

PF-08057418

solution or tablet (fasted/fed)

OTHER

Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.)

solution or tablet (fasted/fed)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-08
Primary Completion
2026-07-23
Completion
2026-07-23
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07575906 on ClinicalTrials.gov